Results 91 to 100 of about 390,020 (313)

Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data

open access: yesBreast Cancer: Targets and Therapy, 2020
Avan J Armaghani, Hyo Sook Han Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USACorrespondence: Avan J Armaghani Email avan.armaghani@moffitt.orgAbstract: Hormone ...
Armaghani AJ, Han HS
doaj  

Revisiting PI3-kinase signalling in angiogenesis

open access: yesVascular Biology, 2019
PI3Ks belong to a family of lipid kinases that comprises eight isoforms. They phosphorylate the third position of the inositol ring present in phosphatidylinositol lipids and, in turn, activate a broad range of proteins. The PI3K pathway regulates primal
Piotr Kobialka, Mariona Graupera
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Influenza A viruses and PI3K signalling

open access: yes, 2008
The influenza A virus non-structural (NS1) protein is multifunctional, and during virus-infection NS1 interacts with several factors in order to manipulate host-cell processes.
Hale, Benjamin G.
core  

Phospho-Akt expression is high in a subset of triple negative breast cancer patients [PDF]

open access: yes, 2014
The most commonly used biomarkers to predict the response of breast cancer patients to therapy are oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2).
Baldacchino, Shawn   +6 more
core   +1 more source

Monkeypox Virus Aggressively Invades via GP120 Domains and PI3K/GTPase-like System of F13 Protein

open access: yes, 2022
Infection with the monkeypox virus (MPXV) causes a condition comparable to that of smallpox, albeit with fewer symptoms and severity. The typical magnitude and duration of monkeypox epidemics will increase as human protection from the smallpox vaccine ...
wenzhong, liu, hualan, li
core   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Targeting potassium channels and autophagy to defeat chemoresistance

open access: yesMolecular & Cellular Oncology, 2020
Both autophagy and hERG1 potassium channels have been shown to promote tumor progression and resistance to treatment. Our findings indicate that the antibiotic clarithromycin can target hERG1 and modulate autophagy to promote the death of chemoresistant ...
Giulia Petroni
doaj   +1 more source

Microglia Mediated Neuroinflammation: Focus on PI3K Modulation

open access: yesBiomolecules, 2020
Immune activation in the central nervous system involves mostly microglia in response to pathogen invasion or tissue damage, which react, promoting a self-limiting inflammatory response aimed to restore homeostasis.
Antonia Cianciulli   +5 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy